Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: InterContinental Hotels Up On Hong Kong Sale

Fri, 10th Jul 2015 10:21

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Friday.
----------
FTSE 100 - WINNERS
----------
InterContinental Hotels Group, up 3.0%. IHG said it has agreed to sell its stake in the InterContinental Hong Kong to Supreme Key for USD938 million. Nomura says the value is at the top end of the broker's appraised value of USD783-940 million, and Numis says this looks like a "very acceptable price" and the achieved price is some USD150 million above its expectation. IHG will retain a 37-year management contract for the hotel, with three ten-year extension rights. It expects to be paid management fees of around USD8 million a year, which will increase after the refurbishment is completed.

International Consolidated Airlines Group, up 2.5%. Irish budget carrier Ryanair Holdings said its board has voted unanimously to accept IAG's offer for its stake in Aer Lingus Group, removing the final barrier in the way of the British Airways and Iberia owner's takeover bid and paving the way for the protracted transaction to go through. IAG made a EUR1.4 billion takeover offer for Aer Lingus late in 2014 and has already secured the Irish government's support for the bid, along with that of the Irish flag carrier's board. Ryanair shares are up 3.0% and Aer Lingus is up 2.1%.

BHP Billiton, up 2.5%. Citigroup upgraded the miner to Buy from Neutral, together with Rio Tinto, which is up 1.3%.
----------
FTSE 250 - WINNERS
----------
Premier Oil, up 5.6% at 147.30 pence. Barclays reiterates its Overweight rating for Premier with a target price of 250.0 pence. The company is making more cost savings than anticipated and is benefiting from its hedging programme, but its portfolio remains highly sensitive to the oil price outlook, and the development of the UK Solan field remains key to its future, say analysts at Barclays.

Brewin Dolphin, up 3.1% at 299.15p. Panmure lifted the investment management and financial planning firm price target to 350p from 300p, keeping a Buy rating.

Petrofac, up 2.9%. The oil company said it has been awarded a project worth around USD780 million to supply engineering, procurement and construction work to assist Kuwait Oil Co's plans to increase oil production. Petrofac said the EPC project work will be completed toward the end of 2017, and focus on Kuwait Oil's manifold trunkline system, which provides feedstock to Kuwait Oil's gathering centres via a network of independent networks and pipelines, it said in a statement.
----------
FTSE 250 - LOSERS
----------
Lonmin, down 3.4%. UBS downgraded the miner to Sell from Neutral.
----------
AIM ALL-SHARE - WINNERS
----------
Reneuron Group, up 21% at 5.88p. The stem-cell company posted a widened pretax loss for its 2015 financial year due to rises in research and development and administrative costs, but said it has placed 1.37 billion shares at 5 pence per share to raise GBP68.4 million to back its therapeutic programmes. Shares in the company closed at 4.875 pence on Thursday.

Aurasian Minerals, up 15%. The South-East Asian focused miner said it has appointed Peter Mullens as its new chief executive, and that Mullens has agreed to subscribe to new Aurasian shares alongside a new non-executive director to raise GBP207,500 for the company. The company said Mullens has over 30 years of experience in mining and exploration geology and is currently a director of Royal Road Minerals, which is listed on the Toronto Stock Exchange. Previously, he had held roles at Lydian International and Aquiline Resources.

Altona Energy, up 10%. The miner said its exploration licences for the Arckaringa coal project in southern Australia have been renewed and said it has signed a formal business relationship with Parsons Brinckerhoff, the US-based engineering and design firm. Altona said the South Australian government has granted 12-month extension to the drilling licences held by Altona at Arckaringa.

Daniel Stewart Securities, down 8.5%. The company named the former chief executive of Sportingbet, the online gaming company sold to GVC Holdings and William Hill in 2013, as an independent non-executive director. Andrew McIver, who will sit on Daniel Stewart's audit committee, is part of the AIM-listed investment bank's efforts to strengthen its board, according to Chairman Peter Shea.
----------
AIM ALL-SHARE - LOSERS
----------
Sefton Resources, down 9.4%. The company said former Executive Chairman Jim Ellerton, who initiated legal proceedings against the company in May, has filed documentation in an attempt to "force the company into bankruptcy proceedings". Ellerton lodged the original legal claim against the company, two directors and one former director in May, claiming damages related to his resignation from the company's board, the termination of his consulting contract and a deal with Hawker Energy. Sefton on Friday said Ellerton has filed an involuntary petition under Chapter 7 of the US bankruptcy code to try to force the company into bankruptcy.
----------

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
11 Mar 2013 08:31

ReNeuron Group wins grants for stem cell therapy development

ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy. The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council. The first award of £0.4m will be used for

Read more
29 Jan 2013 10:29

ReNeuron Group edges further in stem cell therapy research for stroke patients

ReNeuron Group received the green light to complete the final stages of first phase safety testing of its ReN001 stem cell therapy for disabled stroke patients in Scotland, the company announced Tuesday. The ReN001 stem cell therapy was being administered in ascending doses to a total of 12 stroke

Read more
5 Nov 2012 08:33

Angel Biotech signs new contract with ReNeuron

Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year. The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients. ReNeuron's ReN001

Read more
17 Oct 2012 07:27

ReNeuron progresses stroke clinical trial

ReNeuron has reported further progress in the clinical trial of its ReN001 stem cell therapy for disabled stroke patients, known as the PISCES study. The third and penultimate batch of three patients have all been successfully treated with ReN001 and discharged from hospital with no acute safety is

Read more
11 Sep 2012 14:25

Small caps round-up: ReNeuron, Havelock, Goodwin

Clinical-stage stem cell group ReNeuron has achieved further significant milestones with its ReN001 and ReN009 programmes in stroke and critical limb ischaemia, with the filing of two further clinical trial applications to progress the clinical development of these novel therapies. Michael Hunt, Chi

Read more
14 Aug 2012 12:35

Small caps round-up: ReNeuron, Eckoh, Healthcare Locums

Clinical-stage stem cell group ReNeuron surged on Tuesday after saying that the Data Safety Monitoring Board gave a favourable recommendation to proceed to the with a higher dose of its ReN001 stem cell therapy in a clinical trial. 'This represents a further important milestone for the study as we m

Read more
28 Jun 2012 14:22

ReNeuron's full-year results disappoint

ReNeuron Group, a UK-based stem cell company, suffered a decline in its share price on Thursday after posting an increase in pre-tax losses for the year ended March 31st. Loss before tax widened from £6.64m to £6.8m year-on-year (y/y), while revenues rose from £0.029m to £0.04m, representing royal

Read more
16 May 2012 15:18

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and impleme

Read more
27 Apr 2012 14:20

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Read more
3 Apr 2012 12:39

Small caps round-up: DQ Entertainment, Tristel, ReNeuron

DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the seco

Read more
11 Jan 2012 10:55

ReNeuron down despite positive data release

In its second announcement of the year, ReNeuron, the Surrey based stem cell developer, has announced new data on the stability of the company's CTX stem cell line. Researchers from University College London are due to tell a conference in San Diego that the results show "CTX cells retained their m

Read more
3 Jan 2012 08:19

ReNeuron announces positive data

Stem cells therapy developer ReNeuron has gained positive data from a recent pre-clinical study which used its ReN001 stem cell therapy for disabled stroke patients. The newly-published data show significantly improved outcomes in the key behavioural tests in the cell-treated group. A gradual im

Read more
13 Sep 2011 15:09

ReNeuron successfully treats first patient

Stem cells therapy developer ReNeuron has successfully treated a stroke patient who underwent the safe, first-time administration of a higher dose of its new drug, ReN001. The firm ran the increased level of the stem cell therapy drug after the independent Data Safety Monitoring Board recommended t

Read more
13 Dec 2010 18:06

ReNeuron cash call will last two years

Stem cell therapies developer ReNeuron is raising £10m from a share issue at 5.5p a share. The cash will finance the pre-clinical and clinical development costs of the main drug programmes, as well as general running costs, for the next two years. The cash will also be used to complete manufacturi

Read more
12 Jul 2010 08:31

Small caps round-up: Ariana Resources, Michelmersh, ReNeuron...

Shares in Ariana Resources rallied after the Turkey-focused gold miner announces the completion of its joint venture agreement with Proccea to develop the Red Rabbit Project in western Turkey. The group said results from the recent resource drilling programme are expected shortly. Managing directo

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.